Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Foghorn Therapeutics (FHTX) over the last 6 years, with Q2 2025 value amounting to $22000.0.

  • Foghorn Therapeutics' Capital Expenditures rose 2941.18% to $22000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $529000.0, marking a year-over-year increase of 1400.86%. This contributed to the annual value of $906000.0 for FY2024, which is 2598.04% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Capital Expenditures of $22000.0 as of Q2 2025, which was up 2941.18% from $28000.0 recorded in Q1 2025.
  • In the past 5 years, Foghorn Therapeutics' Capital Expenditures registered a high of $1.8 million during Q1 2021, and its lowest value of $17000.0 during Q2 2024.
  • Its 5-year average for Capital Expenditures is $372388.9, with a median of $258000.0 in 2022.
  • As far as peak fluctuations go, Foghorn Therapeutics' Capital Expenditures crashed by 9893.18% in 2021, and later soared by 119459.46% in 2024.
  • Over the past 5 years, Foghorn Therapeutics' Capital Expenditures (Quarter) stood at $80000.0 in 2021, then surged by 236.25% to $269000.0 in 2022, then tumbled by 86.25% to $37000.0 in 2023, then surged by 1194.59% to $479000.0 in 2024, then plummeted by 95.41% to $22000.0 in 2025.
  • Its Capital Expenditures stands at $22000.0 for Q2 2025, versus $28000.0 for Q1 2025 and $479000.0 for Q4 2024.